NASDAQ:NERV
Minerva Neurosciences Stock News
$2.50
+0.0400 (+1.63%)
At Close: May 22, 2024
Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Monday, 06'th May 2024
Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
07:30am, Wednesday, 01'st May 2024
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv
US FDA declines to approve Minerva Neurosciences' schizophrenia drug
08:14am, Tuesday, 27'th Feb 2024
Minerva Neurosciences said on Tuesday the U.S. Food and Drug Administration has declined to approve its experimental drug for the treatment of negative symptoms in patients with schizophrenia.
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
07:00am, Thursday, 22'nd Feb 2024
BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
07:30am, Tuesday, 07'th Nov 2023
BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Minerva Neurosciences: There's Probably Time For One More Rally
04:05am, Wednesday, 23'rd Aug 2023
Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private placement. Boehringer is itself developing a drug for
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
07:30am, Tuesday, 01'st Aug 2023
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
08:30am, Wednesday, 28'th Jun 2023
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now
10:57am, Friday, 09'th Jun 2023
Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreemen
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
02:11pm, Monday, 05'th Jun 2023
Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.
Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead
05:34pm, Friday, 19'th May 2023
NERV has once again run on the submission of an NDA for roluperidone for the treatment of negative symptoms in schizophrenia. There will be no Refusal to File letter this time, with NERV using a dispu
What Makes Minerva Neurosciences (NERV) a New Buy Stock
01:02pm, Thursday, 18'th May 2023
Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
07:30am, Monday, 15'th May 2023
BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner
FDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26, 202
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
08:30am, Monday, 08'th May 2023
BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner
